Brief: Bcal Diagnostics Annouces A$2.4M Capital Raise To Further Breastest Commercialisation
28/08/2023 02:49
Aug 28 (Reuters) - BCAL Diagnostics Ltd BDX.AX :
* A$2.4M CAPITAL RAISE TO FURTHER BREASTEST
COMMERCIALISATION
* PLACEMENT AT AN OFFER PRICE OF A$0.10 PER NEW SHARE
Source text for Eikon: ID:nASX4gQ4dd
Further company coverage: BDX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BCAL Diagnostics
See all newsAustralia's Genetic Signatures urges largest stakeholder to clarify merger intentions; shares rise
Brief: BCAL Diagnostics Introduces Avantect Multi-Cancer Early Detection Test
Brief: BCAL Diagnostics Clarifies Of Bcal's Position In Relation To Genetic Signatures
Brief: Genetic Signatures Requested BCAL Diagnostics To Clarify Details Of Shareholdings, Associates In Co
Brief: BCAL To Acquire Shares In Genetic Signatures